Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Declan Doogan, MD has served as a director since February 2021. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion-dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). |
| 2022-04-28 | Declan Doogan, MD, has served as a director since February 2021. Our Board of Directors believes that Dr. Doogan’s 30 years of experience in the global pharmaceutical industry in both major pharmaceutical and biotechnology companies, in addition to his medical background, experience in clinical development and extensive board experience on both public and privately held life sciences companies, qualify him to serve on our Board. The Board has determined that Dr. Doogan is an independent director. He serves on the Corporate Governance and Nominating Committee. |
| 2023-04-28 | Declan Doogan, MD has served as a director since February 2021. ... Our Board of Directors believes that Dr. Doogan’s 30 years of experience in the global pharmaceutical industry in both major pharmaceutical and biotechnology companies, in addition to his medical background, experience in clinical development and extensive board experience on both public and privately held life sciences companies, qualify him to serve on our Board. ... The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. ... The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2022: Declan Doogan, MD 48,500 fees earned or paid in cash, 2,607 option awards, total 51,107. |
| 2023-10-27 | Declan Doogan, MD 182,458 * |
| 2024-04-26 | Declan Doogan, MD has served as a director since February 2021. Our Board of Directors believes that Dr. Doogan’s 30 years of experience in the global pharmaceutical industry in both major pharmaceutical and biotechnology companies, in addition to his medical background, experience in clinical development and extensive board experience on both public and privately held life sciences companies, qualify him to serve on our Board. The members of the Corporate Governance and Nominating Committee are currently Drs. Almenoff and Doogan and Mr. Proehl. The following table summarizes the compensation paid to non-employee directors for fiscal year ended December 31, 2023: Declan Doogan, MD 48,500. |
| 2024-09-27 | Declan Doogan, MD 48,500 |
Data sourced from SEC filings. Last updated: 2025-07-01